natgillin/translations-raw huggingface dataset:
A vaccine composition, comprising: a peptide fragment consisting of no more than 25 consecutive amino acids of indoleamine 2,3-dioxygenase (IDO) of SEQ ID NO: 1, 
imunogenski aktivni peptidni fragment indoleamin 2,3-dioksigenaze (IDO) sa SEQ ID NO:1, koji se sastoji od najviše 25 uzastopnih aminokiselina sa SEQ ID NO:1 koje sadrže sekvencu SEQ ID NO:6; i
PTA-7045 to human TNFa; and (ii) binds to a neutralizing epitope of human TNFa with an affinity of at least 1 x 108 liter/mole, measured as an association constant (Ka). 
PTA-7045 za ljudski TNFo; 1 (fi) veže neutralizirajući epitop ljudskog TNFa. s afinitetom od najmanje 1 x 10* litara/molu, mjereno konstantom asocijacije (Ka).
The use of claims 1 to 10, wherein said transdermal dosage form is selected from the group consisting of a topical gel, a lotion, an ointment, a transmucosal system, a transmucosal device, and an iontophoretic delivery system. 
Korištenje iz zahtjeva 1 do 10, naznačeno time da je navedeni transdermalni oblik doziranja odabran iz grupe koja se sastoji od lokalnog gela, losiona, pomasti, transmukozalnog sustava, transmukozalnog uređaja te iontoforetskog sustava izdavanja.
is independently phenyl substituted with 0-3 R6 or pyridinyl substituted with 0-2 R6; 
R' je nezavisno fenil supstituiran na 0-3 R5ili piridinil supstituiran na 0-2 R';
with methylamine under suitable reductive amination conditions to form the compound of formula 2b. 
Nue/ < zana ib s metilaminom u pogodnim reduktivnim aminacijskim uvjetima.
Preferably the antibody selected in step (c) in the above methods inhibits the binding of an HLA-C allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of an HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
HLA-c alel molekule koja ima Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
the composition is suitable for human or animal ingestion; and 
(b) je pripravak pogodan za upotrebu od strane čovjeka ili životinje; i
and R5, the same or different, are selected from linear or branched C1-C20, preferably C1-C15, alkyl groups, C3-C30, preferably C4-C15, cycloalkyl groups, C6-C30, preferably C6-C15, aryl groups, more preferably are selected from methyl, ethyl, n-propyl, iso-propyl, tert-butyl, cyclopentyl, cyclohexyl, phenyl; 
R> se bira između nerazgranatih ili razgranatih Ci-C29 alkilnih skupina, C3-C39 cikloalkilnih skupina; - Rai Rs, iste ili različite, se bira između nerazgranatih ili razgranatih C;-C2o alkilnih skupina, C3-C39 cikloalkilnih skupina, C$-Cso arilnih skupina, a poželjnije ih se bira između metila, etila, n-propila, iso-propila, tert-butila, ciklopentila, cikloheksila, fenila;
A method of treating cancer involving cancer cells expressing CLD18A2, comprising administering to a subject an antibody of any of claims 1, 26, or 27 . The method of claim 35 wherein the cancer is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder, and the metastases thereof. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 6 naznačeno time, što bolest ili poremećaj je bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz skupine koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma pankreasa, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave-vrata, karcinoma žučne vrećice i njihovih metastaza.
The lower capsule ejector 20 is in a position where the outer rim portion of the capsule 24 will sandwich the annular member 34 of the lower capsule ejector 20 with regard to the lower frame 6. 
Donja naprava za izbacivanje čahure 20 je u položaju u kojemu će vanjski rub predjela čahure 24 spojiti kao sendvič prstenasti element 34 donje naprave za izbacivanje čahure 20 u odnosu na donji okvir 6.
An (aza)indole derivative as claimed in claim 4, wherein the group represented by the general formula: is a group represented by the following general formula (IIa): in the formula, Z1 and Z3 represent CH, and Z2 represents N; and Y1 represents a hydrogen atom, hydroxy or a halogen atom, or a prodrug thereof, or a pharmaceutically acceptable salt thereof. 
predstavlja hidroksi ili atom halogena; i predstavlja atom vodika, hidroksi ili atom halogena, ili njegov prolijek, ili farmaceutski prihvatljiva sol. Derivat (aza)indola prema bilo kojem od zahtjeva 1 do 5, koji je predstavljen sljedećom općom formulom (IA) [Kem. 9] [image] u formuli, R1 ima isto značenje kako je definirano u zahtjevu 1, ili njegov prolijek, ili farmaceutski prihvatljiva sol.
a DNA-targeting segment comprising a nucleotide sequence that is complementary to a target sequence in a target DNA, and 
(i) segment koji cilja na DNK 1 koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK, i
Upwardly oriented storage according to claim 1, comprising an overflow opening (160) arranged in an upper part of said storage for providing communication from the interior space to a supplementary storage volume (161). 
Prema gore orijentirano skladište prema patentnom zahtjevu 1, 2, 3, 4 ili 5, koje sadrži otvor za prelijevanje (160) postavljen u gornjem dijelu navedenog skladišta za omogućavanje veze unutrašnjosti skladišnog prostora s dodatnim obujmom (161) za skladištenje.
The antibody of any of claims 1 to 9 for use in the treatment of a pathology associated with Mac-1 binding to fibrin or Mac-1 binding with fibrinogen, wherein said pathology is selected from the group consisting of multiple sclerosis, wound healing, lung ischemia, spinal cord injury, Alzheimer's Disease, stroke, Rheumatoid Arthritis and cancer. 
Protutijelo 1z bilo kojeg od patentnih zahtjeva 1 do 9 za uporabu u liječenju patologije povezane s vezanjem Mac-1 za fibrin ili vezanje Mac-1 s fibrmogenom, pri čemu je navedena patologija odabrana iz grupe koja se sastoji od multiple skleroze, zacjeljivanja rana, ishemije pluća, ozljede kralježnične moždine, Alzheimerove bolesti, moždanog udara, reumatoidnog artritisa i raka.
wherein the system comprises a storage vessel the volume of which is larger than the mixer's volume, and feeding new mass to be treated from said storage vessel into the grinding system. 
gdje sustav sadrži spremišnu posudu čiji je volumen veći od volumena miješalice, gdje se novu masu koju treba obraditi dodaje iz navedene spremišne posude u sustav za mljevenje.
The invention will now be described by way of example only. 
Izum će sad biti opisan pomoću primjera.
Table without number of events (for body of the clinical study report) 
(97) Broj objave europske prijave patenta: EP 2781212 A1
The method of claim 1, further comprising pumping the first portion of the refrigerant through a conduit before mixing the lubricating oil therewith. 
Postupak prema Zahtjevu 1, koji dalje sadrži pumpanje prve količine rashladnog sredstva kroz vod prije njegovog miješanja s uljem za podmazivanje.
The resulting turbid reaction mixture was stirred for 4 h while allowing it to warm to room temperature. 
Dobivena mutna reakcijska smjesa je miješana 4 sata uz istovremeno omogućavanje da se zagrije do sobne temperature.
The therapeutic agent according to claim 23, wherein the disease with a highly expressed human CDH3 is cancer. 
Terapijsko sredstvo, namijenjeno upotrebi u skladu s patentnim zahtjevom 12, naznačeno time što je bolest rak dojke.
According to another aspect of the above embodiment, a method is provided wherein the starting material in step a) comprises a water miscible organic solvent in the range of 10% v/v. 
Postupak prema zahtjevu 4, naznačen time da vodena otopina koja sadrži otopljenu sol Micafungina u koraku a) sadrži organsko otapalo koje se miješa s vodom u rasponu od 10 % v/v.
A method for transmitting broadcasting data in a receiver, the method comprising: 
Postupak odašiljanja radiodifuzijskih podataka prijemniku naznačen time da sadrži:
The vaccines disclosed herein may use any suitable Haemophilus influenzae type B antigen. The antigen may be capsular saccharide (PRP) from Haemophilus influenzae type B conjugated to a carrier protein (Hib). 
Cjepivo u skladu s patentnim zahtjevima 1-6, naznačeno time što dodatno sadrži konjugat proteinskog nosača s saharidom iz kapsule bakterije Haemophilus influenzae tip B (Hib), izborno apsorbiran na aluminijev fosfat ili neapsorbiran na adjuvans.
from a compound of the Formula X: 
ZD6474 iz spoja sa formulom X:
A method of claim 9, wherein said cancer is selected from the group consisting of: brain (gliomas), glioblastomas, leukemias, lymphomas, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, colon, gastric, bladder, head and neck, kidney, lung, liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma, osteosarcoma, giant cell tumor of bone and thyroid. The use of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for use in the treatment of a disorder mediated by inhibiting EZH2. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, ili upotreba u skladu s patentnim zahtjevom 6, naznačeni time što se navedeni rak bira iz skupine koju čine: rak na mozgu (gliomi), glioblastomi, leukemije, limfomi, Bannayan-Zonanin sindrom, Cowdenova bolest, Lhermitte-Duclosova bolest, rak dojke, upalni rak dojke, Wilmsov tumor, Ewingov sarkom, rabdomiosarkom, ependimom, meduloblastom, rak debelog crijeva, rak želuca, rak mokraćnog mjehura, rak glave i vrata, rak bubrega, rak pluća, rak jetre, melanom, rak bubrežnih stanica, rak jajnika, rak gušterače, rak prostate, sarkom, osteosarkom, gigantocelularni tumor kosti i rak štitnjače.
recovering and, optionally, purifying the heterologous glycoprotein, wherein said Trichoderma or Myceliophthora cell comprises one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental Trichoderma or Myceliophthora cell which does not have said mutation(s), and wherein N-glycosylation site occupancy of the heterologous glycoprotein expressed in the Trichoderma or Myceliophthora cell is at least 90% and wherein the heterologous glycoprotein is a mammalian glycoprotein and wherein the yield of the mammalian glycoprotein is at least 1 gram per liter. 
obnovu te eventualno, purifikaciju heterolognog glikoproteina, pri čemu navedena stanica gljivice Trichoderma ili Myceliophtora obuhvaća jednu ili više mutacija koje smanjuju ili zaustavljaju jednu ili više aktivnosti endogene proteaze u odnosu na roditeljsku stanicu gljivice Trichoderma ili Myceliophtora, koja nema navedene mutacije, pri čemu je popunjenost mjesta N-glikozilacije heterolognog glikoproteina izražena u stanici gljivice Trichoderma ili Myceliophtora najmanje 90%, pri čemu je heterologni glikoprotein glikoprotein sisavaca i pri čemu je prinos glikoproteina sisavaca najmanje 1 gram po litri.
for a compound of Formula I wherein R1 is reacting a compound of the formula with a compound having the formula where R' is C1-C6 alkyl or aryl optionally substituted with C1-C6 alkyl, in the presence of a base; 
S-CHR6aR6b gdje R6a je piperidinil (po izboru supstituiran s C1-C6 alkil, CO2-(C1-C6 alkil) ili (C1-C6 alkil)OH) ili struktura formule [image] i
Use of a compound represented by the formula (I) wherein R1 is as defined in claim 1, or a salt thereof, for manufacture of an agent for the prophylaxis or treatment of diseases in which insulin resistance is involved. 
N. CH3CH,O- N (I) gdje R! je kao definiran u zahtjevu 1, ili njegova sol, za proizvodnju sredstva za profilaksu ili liječenje oboljenja u kojima je sadržana inzulinska rezistencija.
Preferably, the ramped portions are separated from one and other by a gap having a width that is greater than or equal to the width of a protrusion on the lower cap closure portion. 
Dispenzer kao što je zahtjevan u patentnom zahtjevu 10, gdje su izdignuti dijelovi odvojeni jedan od drugog pomoću međuprostora koji ima širinu koja je veća od ili jednaka sa širinom ispupčenja na donjem dijelu za zatvaranje poklopca.
The pressure chamber 8 is now limited by a sealing between the base part 5 and the base unit 3 at a collar 23 on the base unit extending downwards from, and substantially in axial extension of, a neck part of the container 2 and an inwardly facing surface of the elevated annular platform 19. 
Tlačna komora $ je sada omeđena s nepropusnim elementom između osnovnog dijela 5 i osnovne jedinice 3 kod prstena 23 na osnovnoj jedinici, koja se proteže od vratnog dijela spremnika 2 prema dolje i uglavnom u aksijalnom smjeru, i povišene prstenaste površine 19 koja gleda prema unutra.
In some instances, delivery of the therapeutic agent or biological material is continuous to the site where treatment is needed, for example, over several weeks. 
Biološki materijal kapsuliran u fibroin svile na način prema postupku iz zahtjeva 12 i 13, za uporabu kao proizvod za dopremu bioloških tvari.
The container 14 is then inserted into the pressure chamber 4 as shown in Fig. 11b . 
- < umetanje spremnika pića (14) u tlačnu komoru (4),
Optionally, prior to administration of pirfenidone at doses of 2400 mg/day or 2403 mg/day, said patient is administered pirfenidone at doses lower than 2400 mg/day for a time period. 
Pirfenidon za upotrebu u liječenju pacijenta prema zahtjevu 2, gdje se prije stupnja (a) spomenutom pacijentu daje pirfenidon u dozama manjim od 2400 mg/dan u tijeku vremenskog perioda.
The method of claim 6, wherein the 4-1BB costimulatory signaling region is encoded by a nucleic acid sequence comprising SEQ ID NO: 17. The method of claim 7, wherein the CD3 zeta signaling domain is encoded by a nucleic acid sequence comprising SEQ ID NO: 18. 
(ili) anti-CD19 scFv je kodirano sekvencom SEQ ID NO: 14; HR P20182202 T1 (iv) signalno područje 4-IBB je kodirano sekvencom SEQ ID NO: 17 i signalno područje CD3 zeta je kodirano sekvencom SEQ ID NO:18;
The 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to claim 1, wherein X is O. 
Derivat 4-fenil-5-okso-1,4,5,6,7,8-heksahidrokinolina u skladu s patentnim zahtjevima 1-8, gdje X je O.
A device according to any of the preceding claims wherein the means for initiating a new secure key generation are adapted to initiate a new secure key generation after each transfer of sensitive data from the first integrated circuitry to the second integrated circuitry and/or after each transfer of sensitive data from the second integrated circuitry to the first integrated circuitry. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se upotrebljava sredstvo za pokretanje generiranja novog sigurnosnog ključa za pokretanje generiranja novog sigurnosnog ključa nakon svakog prijenosa osjetljivih podataka iz prvog integriranog kruga (10) u drugi integrirani krug (20) i/ili nakon svakog prijenosa osjetljivih podataka iz drugog integriranog kruga (20) u prvi integrirani krug (10).
Some of these tablets were provided with a coating as described in Example 1. 
Neke od tableta omogućene su u obloženom obliku kako je opisano u Primjeru 1.
The pharmaceutical composition of any one of claims 1-5, wherein the oligosaccharide chain comprises at least one branch having the structure NeuNAc2a3GalB4GlcNAcB2Mana6. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da oligosaharidni lanac sadržava najmanje jednu granu koja ima strukturu NeuNAc20a3Galp4GlcNAcB2Mana6.
wherein the step of adjusting the speed and/or the torque of the bobbin (2) comprises the steps of comparing the measured tension value of the yarn (F) with the reference tension value and determining said value of the speed and/or torque to impart to said bobbin (2). 
gdje se korak podešavanja brzine i/ili zakretnog momenta kalema (2) sastoji u koracima uspoređivanja izmjerene vrijednosti napetosti niti (F) s referentnom vrijednosti napetosti i određivanja navedene vrijednosti brzine i/ili zakretnog momenta koje treba prenijeti na navedeni kalem (2).
a protein-binding segment that interacts with said chimeric Cas9 protein, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, wherein said contacting is in vitro or in a cell ex vivo. 
segment koji veže protein, te koji djeluje zajedno s navedenim polipeptidom Cas9, pri čemu segment koji veže protein obuhvaća dva komplementarna nukleotidna odsjeka koji hibridiziraju kako bi tvorili RNK dvostruke strukture (dsRNK)-dupleks; te time, da su navedena dva komplementarna nukleotidna odsjeka kovalentno vezana putem interventnih nukleotida.
These results also suggest a potential role for TLK199 in treating chemotherapy-induced cytopenias. 
Ovi rezultati također sugeriraju potencijalnu ulogu za TLK 199 u tretiranju kemoterapijom inducirane citopenije.
A glassy lozenge according to claim 36 having a mass of 2 to 3 grams. 
Staklasta tableta-pastila prema patentnom zahtjevu 39, naznačena time što ima masu od 2 do 3 grama.
For example the rosette has a large number of cooperating parts and springs for each radially displaceable segment, and a special release mechanism to spread the segments when the bottle needs to be replaced. 
Na primjer, rozeta ima velik broj dijelova koji djeluju zajedno s njom i opruge za svaki radijalno pomičan segment, te naročiti mehanizam za rasterećenje da bi se segmenti raširili kad treba zamijeniti bocu.
O-(monocyclic saturated hetero ring group), or 
CO-(skupina monocikličkih nezasićenih hetero-prstena koji sadrže dušik),
The method of claim 7, wherein said animal feed supplement is a lick block or is pelletized. 
Postupak prema zahtjevu 7, naznačen time da je navedeni dodatak hrani za životinje blok za lizanje ili je u obliku peleta. nosne
The pharmaceutical composition as defined in Embodiment 65 comprising a therapeutically effective amount of the (S)-PG crystal structure and a pharmaceutically acceptable carrier or diluent. E-67. 
Farmaceutski pripravak kako je definirano u zahtjevu 9 naznačen time da sadrži terapeutski učinkovitu količinu kristalne strukture mono (S)-propilen glikol mono hidrata (S)-PG 1 farmaceutski prihvatljiv nosač ili razrjeđivač.
The composition according to claim 4, wherein the amount of mannitol and microcrystalline cellulose, as an intragranular component, is about 50 weight percent. 
Pripravak u skladu s patentnim zahtjevom 4, pri čemu je količina manitola i mikrokristalne celuloze, kao intragranularne komponente, oko 50 masenih postotaka.
CBA is a cell binding agent, which is the humanized anti-DLL3 antibody M; 
CBA je sredstvo za vezanje stanice koje je protutijelo anti-DLL3;
according to the standardized mobile communication technology, or according to an alternative standardized mobile communication technology, wherein during a second time interval, the antenna device is used for transmitting and/or receiving radio frequency signals according to a further mobile communication technology, wherein the first time interval and the second time interval are alternating, and wherein the second carrier frequency (120) is a frequency in a frequency range out of the following: 
- prema standardiziranoj mobilnoj komunikacijskoj tehnologiji, ili - prema alternativnoj standardiziranoj mobilnoj komunikacijskoj tehnologiji, pri čemu se za vrijeme drugog vremenskog intervala, antenski uređaj koristi za predaju iili prijem radio frekventnih signala na drugoj nosećoj frekvenciji (120) u skladu sa slijedećom mobilnom komunikacijskom tehnologijom, pri čemu su prvi vremenski interval 1 drugi vremenski interval naizmjenični, 1 pri čemu je druga noseća frekvencija (120) frekvencija u frekventnom opsegu između slijedećih:
the coding unit of the current depth is split into coding units of a lower depth, independently from neighboring coding units; and 
određuje jedinicu predviđanja trenutne jedinice kodiranja podjelom trenutne jedinice kodiranja na barem jednu jedinicu predviđanja;
The ActRIIa-Fc fusion protein for use according to claim 4, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:2. 
Farmaceutska smjesa iz zahtjeva 1 ili 2, naznačena time, što se ActRIIa-Fc fuzijski protein rekombinantno eksprimira u CHO stanicama, uz korištenje TPA liderske sekvence SEQ ID NO: 9.
wherein PG is a protection group, thereby obtaining a compound of formula X (Compound X): and deprotecting Compound X to obtain Compound VII or converting Compound X directly to Compound I. 
- < uklanjanje zaštite Spoja X radi dobivanja Spoja VII ili pretvorba Spoja X izravno u Spoj I, gdje su Spoj IX 1 X kako slijedi:
A method for stabilizing a herbicidal sulfonylurea compound which is at least one member selected from the group consisting of nicosulfuron and flazasulfuron or its salt in a water-based herbicidal suspension by using an inorganic salt, and at least one sulfonate selected from the group consisting of an alkylbenzene sulfonate, an alkylnaphthalene sulfonate, an alkylbenzene sulfonate condensed with formaldehyde and an alkylnaphthalene sulfonate condensed with formaldehyde; 
Postupak za stabilizaciju herbicidnog spoja sulfoniluree, naznačen time, da je taj spoj barem jedan od članova odabran iz skupine koja se sastoji od nikosulfurona i flazasulfurona ili njegove soli u herbicidnoj suspenziji na bazi vode pomoću anorganske soli i najmanje jednog sulfonata odabranog iz skupine koja se sastoji od alkilbenzen sulfonata, alkilnaftalen sulfonata, alkilbenzen sulfonata kondenziranog s formaldehidom i alkilnaftalen sulfonata kondenziranog s formaldehidom;
SQTRHVPYT within a human light chain variable region originating from the amino acid sequence disclosed in GenPept entry CAA51135 (SEQ ID No:24). 
CDRL3: SQTRHVPYT (SEQ ID No:6) unutar okvira varijabilnog područja ljudskog lakog lanca podrijetlom iz aminokiselinskog slijeda opisanog u SEQ
Mobile station device, mobile communication system, and communication method 
UREĐAJ MOBILNE STANICE, MOBILNI KOMUNIKACIJSKI SUSTAV, TE POSTUPAK KOMUNIKACIJE
Process according to claim 39 or 40, wherein the caramelised feedstock contains at least 50% by weight of dry matter of brewing adjuncts, including at least 5% caramel by weight of dry matter. 
Postupak prema zahtjevu 39 ili 40, naznačen time, što karamelizirana sirovina sadržava najmanje 50% po masi suhe tvari pivarskih dodataka, uključujući najmanje 5% karamele, po masi suhe tvari.
The use of any one of claims 8 to 11, further comprising co-administering an effective amount of an anti-migraine agent, anti-epileptic agent, anti-diarrheal agent, or anti emetic. 
Uporaba prema bilo kojem od zahtjeva 8 do 11, naznačena time da nadalje sadrži zajedničko davanje učinkovite količine sredstva protiv migrene, anti-epileptičkog sredstva, sredstva protiv proljeva ili sredstva protiv povraćanja.
Test Compositions and Comparative Compositions were then placed in polybags which were sealed and stored at either 25° C./60% RH or 30° C./65% RH for a period of 1, 3, or 6 months. At the end of storage, capsules were opened and peroxide value of the fill material was analyzed. 
Farmaceutski pripravak prema zahtjevu 1, naznačen time da nakon skladištenja pripravka na 25 "C i 60% RH kroz period od 6 mjeseci, EPA ima drugu peroksidnu vrijednost ne veću od 7 Meq/kg, ili ne veću od 6 Meq/kg.
More particularly, the invention relates to a monoclonal antibody, or a divalent functional fragment or derivative thereof, as above described characterized in that it also comprises a hinge region comprising the amino acid sequence SEQ ID No. 
rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, također sadrži zglobnu regiju koja sadrži aminokiselinsku sekvenciju SEQ ID No.
Crohn's disease or ulcerative colitis) and bladder disorders. 
Crohnova bolest 1li ulcerativni kolitis) i poremećaja mokraćnog mjehura.